Eden Research plc, the AIM-listed company that provides natural microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, has signed a collaboration and license agreement with Intellectual Ventures’ Invention Development Fund, to strengthen and expand Eden’s Intellectual Property portfolio while providing Eden with access to IV’s world-leading IP-related services and global network of licensing and business development professionals.
Under the Agreement, IDF’s expertise and global position will help enhance and add value to Eden’s IP portfolio and presence in key regions around the world with a particular emphasis on Asian, North American, and South American markets. Eden and IDF will collaborate on the sourcing and development of next-generation technologies for the agricultural, animal health, food ingredients, human health and personal care markets. Eden and IDF will also pursue licensing opportunities from IDF’s substantial patent portfolio to support Eden’s current and future business.
Sean Smith, chief executive officer of Eden, said, “By partnering with IDF we are helping to ensure that our partners receive the full benefits of access to Eden’s technologies which are supported by a comprehensive and secure global patent portfolio. Eden will utilise IDF’s unique “invention engine” to enhance and extend our core intellectual property portfolio and expand our technology base in areas outside of our current focus. IDF’s global presence will also help us to increase our market presence outside Europe more efficiently and rapidly. IV is one of the world’s largest patent owners and is considered the global leader in monetising intellectual property assets. As a technology development and licensing company, the benefits of such a partnership are clear.”
Chris Alliegro, executive vice president of IV and Head of IDF, said, “Intellectual Ventures helps create a world where invention can thrive through a commitment to research, collaboration, investment and inventors’ rights. We are pleased to work with Eden to help strengthen both its IP and future technologies.”